Meilleur Technologies Inc. Announces Execution of Manufacturing Agreement with PharmaLogic for Production of the Next-Generation Amyloid PET Imaging Biomarker, NAV4694
Knoxville, TN and Boca Raton, FL - December 20, 2023— Meilleur Technologies Inc. (MTI) today announced it has signed an agreement with PharmaLogic Holdings Corporation (“PharmaLogic”) granting PharmaLogic the rights to manufacture fluorine-18[F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography (PET) imaging studies to assess the status of amyloid plaque in the brain. Amyloid plaques are one of the pathological hallmarks of several neurodegenerative diseases, including Alzheimer’s Disease (AD).
Under the terms of the agreement, PharmaLogic will manufacture [F18]NAV4694 for use in clinical trials at select United States-based radiopharmacies.
“We are delighted that the NAV-694 clinical and research program will be supported by Pharmalogic's extensive PET manufacturing and dispensing expertise,” said Rick Hiatt, President and CEO of Meilleur Technologies, Inc. “Meilleur is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative disease. Additionally, we believeNAV4694 has unique properties that will prove useful in developing current and future therapeutic agents in neurodegenerative disease and are excited to add PharmaLogic to our growing network of pharmaceutical and academic partners. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”
“PharmaLogic is pleased to partner with Meilleur Technologies furthering our commitment to help combat some of the world's most challenging diseases, including Alzheimer's Disease.” said Steve Chilinski, CEO of PharmaLogic.
About Meilleur Technologies, Inc.
Meilleur’s vision is to be the premier provider of imaging biomarkersfor neurological pathologies, associated information technology and relatedtools to accelerate the development, approval, and adoption of effectivetherapies to treat neurodegenerative diseases. Meilleur’s late-stage biomarker, NAV-4694, provides Pharma and Academicresearchers with a ‘best in class’ second generation ß-Amyloid imaging biomarker capable of detecting andvalidating Disease Modifying Therapies with the highest possible precision andaccuracy for determining the risk of Alzheimer’s disease.
PharmaLogic is a world-class North American contract development andmanufacturing organization specializing in novel diagnostic imaging andtherapeutic radiopharmaceuticals for the treatment of cancers and other diseases. In addition to an established and reliable network ofradiopharmacies, PharmaLogic has decades of expertise in drug development fromdiscovery, through manufacturing and commercialization. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefitof patients worldwide. For more information, visit: www.radiopharmacy.com
Meilleur Technologies, Inc. | Rick Hiatt, +1 617-906-2715
PharmaLogicHoldings Corporation | Taylor Prejna, +1 571 595 8258
Explore Other News